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On-treatment measurements of circulating tumor DNA during
FOLFOX therapy in patients with colorectal cancer
Tina Moser 1,10, Julie Waldispuehl-Geigl1,10, Jelena Belic1,9, Sabrina Weber1, Qing Zhou1, Samantha O. Hasenleithner 1, Ricarda Graf1,
Jasmin Alia Terzic2, Florian Posch2, Heinz Sill 3, Sigurd Lax 4, Karl Kashofer5, Gerald Hoefler5, Helmut Schoellnast6, Ellen Heitzer 1,7,8,
Jochen B. Geigl 1, Thomas Bauernhofer 2✉ and Michael R. Speicher 1,7✉
We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy,
by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not
observe a spike in ctDNA as a sign of a responsive tumor, but instead ctDNA levels initially decreased and remained low in patients
with stable disease or partial response. Our observations reveal further insights into cell destruction during chemotherapy with
important implications for the management of patients.
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INTRODUCTION
Colorectal cancer (CRC) represents a major public health problem
as one of the most frequent solid cancers1. Cell-free DNA (cfDNA),
which contains circulating tumor DNA (ctDNA) in patients with
cancer, is an emerging biomarker in precision oncology2, as ctDNA
reflects CRC tumor burden3 and early ctDNA dynamics may
predict the outcome of chemotherapy4,5. However, despite these
promising prospects, many features of ctDNA as a biomarker
remain unknown. The aim of our study was to address one of
these unknowns, i.e., the on-treatment ctDNA effects during
chemotherapy.
RESULTS
We studied a cohort of 13 patients (DR1-DR13) with the inclusion
criteria of metastasized CRC and progressive disease under one of
the most widely used chemotherapies, i.e., FOLFOX (FOLinic acid
(leucovorin), Fluorouracil (5-FU), OXaliplatin; Supplementary Note
1 and Supplementary Note 2; Supplementary Table 1; Fig. 1a).
FOLFOX is administered over a 48-h period and continuously
destroys dividing cancer cells (ref. 6; Supplementary Note 1). In
order to capture treatment-associated release of ctDNA, we used a
tight blood collection schedule: The baseline (T1) and the last (T9)
blood samples were drawn before and after FOLFOX treatment,
respectively, whereas seven further blood samples (T2 to T8) were
collected during administration (Fig. 1a) with the exception of
DR6, from whom we received only six blood samples. Two
patients, i.e., DR5 and DR10, were excluded due to withdrawn
consent or treatment status.
For all patients, we established the KRAS mutation status from
tumor tissues and in a subset, we additionally sequenced TP53 and
BRAF (Supplementary Table 1; Fig. 1a). Somatic mutations in these
genes are prime trunk mutant alleles in CRC, which were shown to
parallel clinical response7. We then started by analyzing all cfDNA
samples for somatic copy number alterations (SCNAs)8 and
determined the respective tumor fractions with the ichorCNA
algorithm9 (Supplementary Fig. 1) (limit of detection (LOD) of 3%
tumor fraction; Supplementary Note 3). In three cases (DR3, DR8,
DR12) with higher colon-derived DNA proportions (≥10%), we
used deep sequencing (LOD 1%)10 to study the fluctuation of the
respective tumor-specific KRAS mutations. In all other cases, we
employed ultra-sensitive methods comprising SiMSen-seq (Sim-
ple, multiplexed, PCR-based barcoding of DNA for sensitive
mutation detection using sequencing)11 and the AVENIO ctDNA
Targeted Kit, which covers 17 genes12 (LOD 0.1% each). The
AVENIO kit was used to test for the presence of further mutations
in selected plasma samples (DR2, DR4, DR9, and DR 13;
Supplementary Note 3) and then to track in all plasma samples
from DR4 five (2 mutations in APC, and one each in KIT, TP53, and
KRAS) and from DR9 two mutations (TP53 and BRAF). We employed
SiMSen-seq to monitor the KRAS (DR1, DR6, DR7, DR11), TP53
(DR13), or KRAS and TP53 (DR2) mutations in all plasma samples.
Extensive performance and consistency assessments demon-
strated high reliability and robustness of the assays (Supplemen-
tary Note 3).
In agreement with previous reports13, we found that advanced
CRC patients had significantly increased amounts of cfDNA per
milliliter of plasma (median: 50.3 ng/ml; range: 11.0–2,602.8 ng/ml)
compared to healthy controls (median: 8.8 ng/ml; range:
2.9–20.8 ng/ml) (Student’s t-test, p < 0.01–0.0001; Fig. 1b; Supple-
mentary Note 3). One patient, DR12, had exceptionally increased
plasma DNA concentrations (Fig. 1b; Supplementary Fig. 2).
In plasma from three patients (DR1, DR2, DR11), the ctDNA
mutant allele frequencies (mAFs) were invariably at levels of 0.4%
or less throughout the entire 48-h treatment cycle (Fig. 1c;
Supplementary Fig. 3), confirming previous reports that there may
be no correlation between the size of the target lesion (diameters
of target lesions were 112 mm and 28mm for patients DR1 and
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DR11, respectively; Supplementary Note 2) and sample mAF in
plasma2,14. In five patients (DR4, DR7, DR3, DR8, DR9) (Fig. 1c), we
observed a decrease of the ctDNA mAF within the first 18–23 h
and after treatment (T9), mAFs were lower than at baseline (T1)
(Fig. 2a–b; Supplementary Fig. 4). However, in the plasma of two
patients (DR6, DR13), the initial decrease of mAFs within the first
23 h was followed by an increase of mAFs higher at T9 than at T1
(Fig. 2c; Supplementary Fig. 5). The mAF fold changes in patient
DR12, who demonstrated remarkably elevated cfDNA (Fig. 1b) and
the highest ctDNA mAFs in plasma, were consistent with an at
best modest decrease of ctDNA (Fig. 1c and 2d). Compared to
barcoding and deep sequencing, the orthogonal ichorCNA
analyses provided established mAFs closely congruent to SCNA-
derived mAFs (Pearson’s R= 0.98, p < 2.2 × 10–16) (Supplementary
Fig. 6), which confirmed the high reliability of our analyses
(Fig. 2b–d).
We also addressed possible mechanisms of DNA release under
therapy, such as apoptosis or necrosis15,16. Necrotic cells release
high-molecular weight DNA15. However, using electrophoresis,
we did not observe any evidence for the presence of such
molecules (Supplementary Fig. 7). Instead, cfDNA fragmentation
patterns were consistent with those previously associated with
release from apoptotic cells, i.e., a modal value of DNA fragments
lengths near 166 bp, which corresponds to the DNA wrapped
around a nucleosome (~147 bp) plus a linker fragment
(~20 bp)17. Importantly, this pattern did not change during
therapy (Fig. 3a). As reported earlier18,19, we also observed that
plasma DNA fragments from CRC patients were shorter than
those of healthy individuals (p < 0.0001) (Supplementary Fig. 7).
Taken together, the plasma DNA fragmentation patterns under
FOLFOX therapy did not differ from those generally observed in
patients with cancer2,18,19.
Finally, comparison of the baseline (T1) mAFs with the mAFs at
all other time points revealed that the most significant mAF drop
was at T5 (p < 0.005), which corresponds to about 23 h after start
of treatment (Fig. 3b). When we applied RECIST (Response
Evaluation Criteria in Solid Tumors) 1.1 criteria20 and compared
patients with stable disease or partial response with those with
progressive disease (Supplementary Note 4), we observed that in
the stable disease/response group, the ctDNA mAFs remained at
decreased levels at the time of our last blood collection, i.e., T9
(between T1 and T5: p= 0.03906; between T1 and T9: p=
0.01563) (Fig. 3c).
DISCUSSION
The main limitation of our study is the modest sample size, which
can be attributed to the considerable logistical efforts and
especially additional burden and discomfort imposed on the
patients due to the tight blood drawing schedule requiring a great
willingness to help on the part of the patient and their families.
Furthermore, patients have to be treated as inpatients for the
numerous blood draws, while FOLFOX is increasingly being
administered on an outpatient basis. As a consequence, there is
Fig. 1 Study outline and plasma parameters. a Schematic overview of the FOLFOX regimen and the time points of blood collection. All
tumor tissues were analyzed for mutations in KRAS, and in some cases, BRAF and TP53 were sequenced as well. b Plasma DNA quantities of the
patients and healthy controls (n= 60) (Student’s t-test; **p < 0.01, ***p < 0.001, ****p < 0.0001). All boxplots indicate the minimum and
maximum value and median (center), and the interquartile range is shown by box and whiskers. c The median mutant allele frequencies
(mAFs) for each plasma DNA analysis and the timing of each blood draw are displayed. Furthermore, the sum of longest diameters (SLD) as
established by CT imaging for the selected target lesions according to RECIST are shown prior to (left side) and after (right side) completion of
the FOLFOX cycle.
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only a small number of other studies with a relative tight
monitoring schedule and all of them have a limited patient
number in common. In patients with non-small-cell lung cancer
(NSCLC), one study analyzed daily kinetic changes of EGFR
mutation levels in urine from nine patients21 and another study
quantified EGFR and KRAS mutations in three patients over
defined time periods, but only in one on a daily basis, i.e., every
24 h22. A further study analyzed pre- and postchemotherapy
Fig. 2 ctDNA level changes during FOLFOX administration. In each panel, the tumor fraction as established by ichorCNA is displayed in red
and the respective mutations in various colors. Before and after the FOLFOX cycle, the sum of longest diameters (SLD) for the target lesions is
displayed. Fold changes in plasma ctDNA mAFs are each displayed in the right panel. a ctDNA levels of two patients (DR4 and DR7) with low
ctDNA mAFs. b Three patients (DR3, DR8, DR9) with ctDNA mAFs that decrease below baseline values during the FOLFOX cycle. For reasons of
clarity, the results of DR8 are shown in the bottom row. c Two patients (DR6, DR13) whose mAFs increased during the last 24 h of the
treatment cycle to values higher than baseline levels. d ichorCNA, KRAS, and SLDs of patient DR12.
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samples in five patients with metastatic prostate cancer within 1 h
of chemotherapy infusion23.
However, to the best of our knowledge, no previous study
conducted a comparable tight sampling schedule from peripheral
blood during an intravenous chemotherapy as we did and this
unique setting allowed us to make unexpected observations. The
most surprising finding was that although drugs such as
oxaliplatin or 5-FU are swiftly distributed throughout tissue and
quickly destroy dividing cells throughout the entire 48-h period of
administration (ref. 6; Supplementary Note 1), we did not observe
a spike in ctDNA in any patient, which may have reflected a rapid
release of tumor DNA into the circulation from responsive tumors.
Instead, we invariably observed a pattern of ctDNA mAF decrease
in all cases. Interestingly, that decreased ctDNA levels at the end of
a therapy may indicate therapy response was also suggested in
the abovementioned NSCLC and prostate cancer studies22,23. In
our study, patients with progressive disease showed a trend
towards a ctDNA mAF increase between T5 and T9 (Figs. 2c and
3c); however, the increase did not reach significant levels, most
likely due to the low patient number.
In conclusion, further studies are clearly required before the
clinical utility can be evaluated. For clinical applications the
optimal timing of ctDNA level measurements, whether in the first
hour posttreatment instead of at day 5 or day 7 or later still needs
to be established. To this end, our work may initiate early dynamic
therapy response modeling and contribute to the establishment
of a real-time personalized treatment response assessment.
METHODS
Blood/sample collection and processing
The study was approved by the Ethics Committee of the Medical University
of Graz (approval number 26–288 ex 13/14 for the study part involving
patients under FOLFOX treatment and 29–272 ex 16/17 for the collection
Fig. 3 cfDNA size patterns and initial associations with treatment response. a cfDNA size profiles determined from paired-end sequencing
data from patients DR6, DR8, and DR13 at time points T1, T5, and T9. b Serial comparison between baseline mAFs (T1) and mAFs at other time
points (*p < 0.05, **p < 0.005, paired Wilcoxon test). The boxplots indicate the minimum and maximum value and median (center), and the
interquartile range is shown by box and whiskers. c Patients with stable disease (SD) or partial response (PR) and very low ctDNA mAFs (DR1,
DR2, DR4, DR7, and DR11) are shown in the upper panel and those with high ctDNA mAFs (DR3, DR8, and DR9) in the center panel. Patients
with progressive disease (PD) (DR6, DR12, and DR13) are displayed in the lower panel.
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and analysis of blood samples from healthy controls) conducted according
to the Declaration of Helsinki. Written informed consent was obtained from
all patients and healthy individuals, respectively.
For each patient, we collected plasma samples prior to initiation of
FOLFOX treatment and during therapy for a total of nine plasma samples
each (Fig. 1a). One exception was patient DR6, for whom we obtained only
eight samples. Nine milliliters of blood were collected into BD Vacutainer®
EDTA tubes containing 10% NBF (BD Biosciences) or Streck tubes. Plasma
was separated as described previously8 and stored at −80 °C prior to DNA
isolation.
The healthy control group consisted of individuals between 20 and 29
years of age (mean 26 years). In addition, we conducted further
comparisons with an age-matched control group from publicly available
data24 (see Supplementary Note 3 for further details).
cfDNA extraction and quantification
cfDNA extraction and quantification were done according to our
experiences from a multicenter study and all details were described
previously25. In brief, plasma DNA was extracted from 2ml of plasma using
the QIAamp Circulating Nucleic Acid Kit (QIAGEN) according to the
manufacturer’s protocol, which included the addition of the same amount
of carrier RNA to each sample. Extracted DNA was quantified by the Qubit
dsDNA HS Assay Kit (Thermo Fisher Scientific) and stored at −20 °C before
analysis.
Tumor genotyping
Tumor tissue was available for all patients and the KRAS mutation status
was assessed from the primary tumor (all patients except DR4) or
metastatic sites (DR4). In addition, the primary tumors from patient DR7,
DR9, and DR13 were examined for changes in TP53 and/or BRAF. The Ion
AmpliSeq Colon and Lung Cancer Panel v2 (Thermo Fisher Scientific), the
Therascreen KRAS Pyro Kit (QIAGEN) or the Idylla KRAS and NRAS-BRAF-
EGFR S492R Mutation Assays (Biocartis) were used to establish the
mutation status in these genes directly from formalin-fixed paraffin-
embedded (FFPE) tissue sections. Tumor genotyping was carried out at the
Diagnostic and Research Institute of Pathology, Medical University of Graz
and at the Department of Pathology, General Hospital Graz II, Graz, Austria.
For 9 of 11 patients (82%), specific mutations were available from the
primary tissue, in one patient (DR4) only metastatic material was available
for molecular profiling and in the tumor of one patient (DR13), no mutation
was identified.
Plasma-seq and ichorCNA analysis
For all samples, shallow whole-genome sequencing (sWGS), i.e., plasma-
Seq8,26, was performed to establish genome-wide copy number alterations.
Shotgun libraries were prepared from 5–10 ng plasma DNA using the
TruSeq DNA Nano Sample Preparation Kit (Illumina, San Diego, CA, USA) as
previously described8,26. Pooled libraries were quantified by qPCR and
sequenced on the Illumina MiSeq or NextSeq platform using paired-end
(2x75bp; n= 47 CRC samples) or single-end mode (1x150bp; n= 51 CRC
samples). In addition, tumor fraction of each sWGS dataset was estimated
using the previously published ichorCNA algorithm9. Samples with a tumor
fraction below 0.03 were evaluated as ctDNA-negative, since this value was
previously defined as the lower limit of sensitivity for detecting the
presence of tumor DNA.
AVENIO ctDNA targeted panel
For mutation profiling, we used the commercially available AVENIO ctDNA
Targeted Kit, which covers 17 genes across 81 kb, including those in the U.
S. National Comprehensive Cancer Network (NCCN) Guidelines, using
hybrid capture targeted enrichment techniques (ALK, APC, BRAF, BRCA1,
BRCA2, DPYD, EGFR, ERBB2, KIT, KRAS, MET, NRAS, PDGFRA, RET, ROS1, TP53,
UGT1A1) (Roche). In brief, sequencing libraries were generated from
10–20 ng of plasma-derived DNA according to the manufacturer’s
instructions. Libraries were quantified by qPCR and the quality was
assessed using a Bioanalyzer High Sensitivity Kit (Agilent Technologies).
Pooled libraries were sequenced on the Illumina NextSeq platform using a
2x150bp paired-end mode. On average, 15 million paired-end reads were
obtained per sample (range 12.7–17.3 M). Sequencing data were analyzed
using the AVENIO ctDNA Analysis Software (Roche) and variant calls were
generated with a customized workflow using defined somatic variant filter
settings. We excluded synonymous variants and variants present with >1%
mutant allele frequency in population frequency databases (ExAC,
gnomAD, 1000genomes).
Simple, multiplexed, PCR-based barcoding of DNA for sensitive
mutation detection using sequencing (SiMSen-seq)
For tracking mutations in plasma samples with low ctDNA levels, we
employed a molecular barcoding approach, SiMSen-seq. First, target-
specific primers were designed to capture each tumor’s selected
mutations. For DR1, DR2, DR6, DR7 and DR11, various KRAS assays were
designed (i.e., KRAS p.Ala146Thr, p.Gly12Asp, p.Gly13Asp). Moreover, for
DR2, we used a 2-plex assay to track a KRAS mutation (p.Gly12Asp) and a
TP53 variant (p.Ser215Gly). For DR13, we monitored a TP53 mutation
(p.Gly245Ser) identified from AVENIO. Target-specific primer sequences
were as follows: KRAS_1-F: TTTACCTCTATTGTTGGATCATATTCGTCCA and
KRAS_1-R: GCCTGCTGAAAATGACTGAATATAAACTTGTG; KRAS-436-2-F:
TTTCAGTGTTACTTACCTGTCTTGT and KRAS-436-2-R: GGCTCAGGACTTAG
CAAGAAGT; TP53_7-F: CCTGGAGTCTTCCAGTGTGATG and TP53_7-R:
GACTGTACCACCATCCACTACAAC; TP53_P223_1-F: CCTCCCAGAGACCCCA
GTT and TP53_P223_1-R: GCGTGTGGAGTATTTGGATGAC.
SiMSen-seq libraries were generated from 20 ng of plasma DNA as
described previously in detail27. In brief, this protocol involves an initial
three PCR cycle step, in which template DNA was tagged and target
regions were enriched using barcoded target-specific primers. During a
second round of PCR, Illumina-specific adapters were attached to barcoded
PCR products. PCR products were purified using the Agencourt AMPure XP
system (Beckman Coulter, Inc). Libraries were quantified using the QIAseq
Library Quant Assay (QIAGEN) and the library quality was assessed using
the Bioanalyzer High Sensitivity DNA Kit (Agilent Technologies). Sequen-
cing was performed on an Illumina MiSeq platform in single-end 150 bp
mode, with a spike-in of 15% PhiX Control v3 (Illumina). Sequencing data
generated by SiMSen-seq were analyzed using Debarcer (De-Barcoding
and Error Correction). At least three reads with the same barcode
(consensus 3) were required to form a valid barcode family.
Establishment of the limit of detection for SiMSen-seq and the
AVENIO assay
The performance of the assays was evaluated using the SeraCare reference
material (Seraseq ctDNA v2), which harbors multiplexed variants in various
genes at defined mutant allele frequencies (mAF). While the wild-type
sample clearly showed negative results, both UMI-based methods were
able to detect variants with a detection limit as low as 0.1% mAF.
Therefore, the analytical sensitivity was set to 0.1% mAF.
Deep sequencing
We conducted targeted deep sequencing for the KRAS p.Gly12Asp, p.
Gly12Val and p.Ala146Thr mutations in all plasma samples from patients
DR3, DR8 and DR12.
Target-specific primer sequences were as follows: KRAS_12_13_F:
AGGCCTGCTGAAAATGACTG and KRAS_12_13_R: TTGTTGGATCATCTT
CGTCCAC; KRAS_A146T_F: TGTGATTTGCCTTCTAGAACAGTAG and KRA-
S_A146T_R: CAGTGTTACTTACCTGTCTTGTCT.
Amplicon libraries were prepared from 1–3 ng plasma DNA as previously
described by our group10. Briefly, target-specific primers were designed to
amplify regions harboring the aforementioned variants and Illumina-
specific adapters were added within a second PCR setup. Amplicon
libraries were sequenced 150 bp paired-end on an Illumina NextSeq or
MiSeq sequencer, obtaining a minimum of 200,000 reads per sample.
Sequencing data were analyzed using an in-house pipeline and mutations
were visualized using Integrative Genomics Viewer (IGV) (version 2.3.58).
Statistical analysis
Statistical analysis was performed using R (version 4.0.2) and the ggpubr
package (version 0.4.0). A p-value of < 0.05 was considered as statistically
significant.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
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DATA AVAILABILITY
The data generated and analyzed during this study are described in the following
data record: https://doi.org/10.6084/m9.figshare.1307891628. The sequencing raw
datasets have been deposited at the European Genome-phenome Archive (EGA;
http://www.ebi.ac.uk/ega/) under study accession number https://identifiers.org/
ega.study:EGAS0000100421329. This study contains the following four datasets: 1:
sWGS of CRC patients (https://identifiers.org/ega.dataset:EGAD00001006101), 2:
Mutation analysis data (AVENIO ctDNA Targeted Kit: https://identifiers.org/ega.
dataset:EGAD00001006103, SiMSen-seq approach: https://identifiers.org/ega.
dataset:EGAD00001006104, Deep sequencing: https://identifiers.org/ega.dataset:
EGAD00001006105). Data access requests can be made to the appropriate Data
Access Committee via the EGA landing page for each dataset. In addition to the
sequencing data, the following data underlie the supplementary figures and tables
of the related manuscript. Summary_file2.xlsx underlies Supplementary table 1
and Supplementary Figs. 8 and 10, and is available from the figshare repository at
https://doi.org/10.6084/m9.figshare.13067348.v230. 41586_2019_1272_MOES-
M2_ESM.xlsx underlies Supplementary fig. 11, and is available in the Supplemen-
tary Tables of Cristiano et al. (2019): https://doi.org/10.1038/s41586-019-1272-624.
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